Short-term Effects Of Dexamethasone Intravitreal Implant For Retinal Macular Edema. A Consecutive Small Case Series
Détails
ID Serval
serval:BIB_EE01CE102DCF
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Short-term Effects Of Dexamethasone Intravitreal Implant For Retinal Macular Edema. A Consecutive Small Case Series
Titre de la conférence
2012 ARVO Annual Meeting
Organisation
2012 ARVO Annual Meeting. Fort Lauderdale, Florida, USA
Adresse
2012 ARVO Annual Meeting. Fort Lauderdale, Florida, USA – 30 aprile – 5 maggio 2012.
Statut éditorial
Publié
Date de publication
03/04/2012
Peer-reviewed
Oui
Volume
53
Pages
508
Langue
anglais
Notes
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 508
Résumé
Purpose:
to evaluate the effectiveness and safety of OZURDEX®(dexamethasone intravitreal implant) 0.7mg in patients with macular edema (ME) due to retinal vein occlusion.
Methods:
this 6-month non randomized case series study collected 15patients with ME due to branch retinal vein occlusion (7 eyes) and central retinal vein occlusion (8 eyes) (BRVO and CRVO respectively). Ophthalmic examination, best-corrected visual acuity (BCVA), intraocular pressure (IOP), fluorescein angiography and optical coherence tomography (OCT), at baseline and each follow-up visit were carried out. Outcome measures included BCVA, central retinal thickness (CRT) by OCT and safety. Mean change of visual acuity (VA), OCT, and IOP was assessed during the follow-up (6 months), using repeated measures analysis of variance, after testing for normality. A linear regression model was also used to evaluate the relationship between OCT and VA, as measured after 6 months of follow-up.
Results:
at baseline all eyes (15) with occlusive ME received DEX Implant700μg. Among these patients all had retinal vein occlusion > 3 months (mean 12.8 ± 7.5). VA, IOP, and OCT at baseline and during the follow up period are summarized in Figure 1. Mean change of VA between baseline and each time point follow-up was not statistically significant (p = 0.2464) with only OCT measurements that showed statistically significant differences with a repeated-measures ANOVA test (p<0.001) at 6 months follow-up. Statistical analysis showed some evidence of benefit on CRT at earlier time points. The peak effects were seen at two months, and there was substantial drop-off between two and three months. Increases in IOP were similar and generally transient following each DEX Implant (p = 0.0929). Simple linear regression analysis showed no statistically significant negative relationship between OCT and VA measured after 6 months (slope -0.00067, 95% CI: -0.0014 - 0.0000488 ).
Conclusions:
in patients with ME due to BRVO and CRVO, DEX Implant 0.7 mg produced substantial improvements in CRT, without, however, improving VA significantly..
Image not available
to evaluate the effectiveness and safety of OZURDEX®(dexamethasone intravitreal implant) 0.7mg in patients with macular edema (ME) due to retinal vein occlusion.
Methods:
this 6-month non randomized case series study collected 15patients with ME due to branch retinal vein occlusion (7 eyes) and central retinal vein occlusion (8 eyes) (BRVO and CRVO respectively). Ophthalmic examination, best-corrected visual acuity (BCVA), intraocular pressure (IOP), fluorescein angiography and optical coherence tomography (OCT), at baseline and each follow-up visit were carried out. Outcome measures included BCVA, central retinal thickness (CRT) by OCT and safety. Mean change of visual acuity (VA), OCT, and IOP was assessed during the follow-up (6 months), using repeated measures analysis of variance, after testing for normality. A linear regression model was also used to evaluate the relationship between OCT and VA, as measured after 6 months of follow-up.
Results:
at baseline all eyes (15) with occlusive ME received DEX Implant700μg. Among these patients all had retinal vein occlusion > 3 months (mean 12.8 ± 7.5). VA, IOP, and OCT at baseline and during the follow up period are summarized in Figure 1. Mean change of VA between baseline and each time point follow-up was not statistically significant (p = 0.2464) with only OCT measurements that showed statistically significant differences with a repeated-measures ANOVA test (p<0.001) at 6 months follow-up. Statistical analysis showed some evidence of benefit on CRT at earlier time points. The peak effects were seen at two months, and there was substantial drop-off between two and three months. Increases in IOP were similar and generally transient following each DEX Implant (p = 0.0929). Simple linear regression analysis showed no statistically significant negative relationship between OCT and VA measured after 6 months (slope -0.00067, 95% CI: -0.0014 - 0.0000488 ).
Conclusions:
in patients with ME due to BRVO and CRVO, DEX Implant 0.7 mg produced substantial improvements in CRT, without, however, improving VA significantly..
Image not available
Mots-clé
retina • vascular occlusion/vascular occlusive disease • edema
Site de l'éditeur
Création de la notice
30/06/2021 10:16
Dernière modification de la notice
09/07/2021 6:37
Données d'usage
